Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
Featured Image

$600M Fund to Support Life Science Innovation

  • Posted by ISPE Boston
  • On August 26, 2019
Vida Ventures, a life sciences venture firm, has announced the closing of Vida Ventures II, raising $600 million in an oversubscribed fund. Vida II will be used to further the firm’s life sciences platform, which began building a successful track record of investing with its inaugural fund by focusing on companies that change the paradigm […]
Read More
 
Featured Image

Cerevel Therapeutics Moving to Cambridge Crossing

  • Posted by ISPE Boston
  • On August 26, 2019
DivcoWest announced today that it has signed a 59,865 square-foot lease with Cerevel Therapeutics at Cambridge Crossing (CX), located at the intersection of Cambridge, Somerville, and Boston. Dedicated to bringing cutting-edge solutions to individuals impacted by nervous system diseases, Cerevel will join Philips North America at 222 Jacobs Street in 2020, making it the third […]
Read More
 
Featured Image

Sarepta Therapeutics Receives Complete Response Letter from FDA

  • Posted by ISPE Boston
  • On August 22, 2019
Sarepta Therapeutics has announced it has received a Complete Response Letter (CRL) from the FDA  regarding its New Drug Application (NDA) seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy (DMD). The CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in […]
Read More
 
Featured Image

Pfizer’s Upjohn + Mylan = Off-Patent/Generics Powerhouse

  • Posted by ISPE Boston
  • On July 31, 2019
Mylan and Pfizer have announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new […]
Read More
 
Featured Image

Lyndra Therapeutics to Collaborate with Gilead on HIV Therapies

  • Posted by ISPE Boston
  • On July 25, 2019
Watertown-based Lyndra Therapeutics recently announced a partnership with Gilead Sciences to develop and commercialize ultra-long-acting oral HIV therapies. This partnership announcement comes just months after Gilead joined Lyndra’s $60.9 million Series B financing round. Gilead will have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV. Lyndra’s ultra-long-acting dosage form has the […]
Read More
 
Featured Image

Kronos Bio Completes $105 Million Financing Round

  • Posted by ISPE Boston
  • On July 25, 2019
“We are excited to have the continued support of high caliber investors who recognize the potential of Kronos’ technology and its team. This financing will help us advance two preclinical programs…, accelerate our research, and further expand the Kronos team in the Boston and San Francisco areas,” said Norbert Bischofberger, Ph.D., President and Chief Executive […]
Read More
 
Featured Image

Frequency Therapeutics Inks $80M Deal with Astellas

  • Posted by ISPE Boston
  • On July 18, 2019
Woburn-based Frequency Therapeutics has entered into an exclusive license agreement with Tokyo’s Astellas Pharma to develop and commercialize Frequency’s regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss, the most common type of hearing loss. At present, there are no approved therapeutic options for sensorineural hearing loss. Frequency will receive an upfront payment […]
Read More
 
Featured Image

BMS Celgene Deal Faces Delays

  • Posted by ISPE Boston
  • On July 18, 2019
Bristol-Myers Squibb recently provided an update on the approval process and timeline for its pending merger with Celgene. To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, BMS is planning the divestiture of its anti-inflammatory drug Otezla (apremilast). The divestiture is subject to further review by […]
Read More
 
Featured Image

Karyopharm Myeloma Drug Receives FDA Approval

  • Posted by ISPE Boston
  • On July 11, 2019
Karyopharm Therapeutics has announced that the FDA has approved its drug Xpovio (selinexor) in combination with dexamethasone for the treatment of certain adult patients with relapsed or refractory multiple myeloma (RRMM). Approval was granted under the Accelerated Approval Program which was developed by the FDA to allow for expedited approval of drugs that treat serious […]
Read More
 
Featured Image

Abbvie to Acquire Allergan for $63 Billion

  • Posted by ISPE Boston
  • On July 11, 2019
AbbVie and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock on June 24, 2019. “This is a transformational transaction for both […]
Read More
 
Page 41 of 56«‹3940414243›»
Post Categories
  • Podcasts (1)
  • Industry Buzz (557)
  • Chapter News (536)
  • Knowledge & Training (79)
  • Students & YP (78)
  • Career Tools (13)
Get Updates via Email




Scroll
Follow Us
Search this Site
@2024 ISPE Boston Chapter. All rights reserved.